Sabu Thomas

#URochesterResearch shows that patients undergoing cardiac resynchronization therapy with defibrillators have lower hospitalization rates and shorter lengths of stay than patients with implantable cardioverter-difibrillators. More in @JAHA_AHA > ahajournals.org/doi/10.1161/JA…

Today is #BlueGreenDay in honor of #DonateLife. Our team made sure to show those colors today. #AHF #heart #fingerlakes #WNY

Proud of our work: CRT‐D significantly reduces both the rate and duration of cardiovascular and HF-related hospitalizations @URMC_DeptMed @SabuThomasMD #MADIT

@JAHA_AHA @VKutyifa @UR_Med @URMC_DeptMed @umichmedicine MADIT‑CRT keeps reinforcing the same signal: earlier, structured intervention changes long‑term trajectories. Reducing HF‑related hospital time isn’t just a device outcome — it’s a systems outcome.

New long-term data from #MADITCRT: In patients with mild heart failure, CRT‐D significantly reduces both the rate and duration of cardiovascular and HF-related hospitalizations compared to ICD alone. @VKutyifa @UR_Med @URMC_DeptMed @umichmedicine ahajrnls.org/4sGWMmp

Cardio-Oncology Update 2025

Home - 6th Annual UR Medicine Cardiac Care Collaborative web.cvent.com/event/6d75160d…

UR Cardiac Care Collaborative! Nov 12, 2025 A multidisciplinary conference on the latest in: AFib, HF, valvular disease, dyslipidemia, cardio-onc, ACS, HTN, amyloidosis & more web.cvent.com/event/6d75160d… @sdent_cardioonc @DeanLisaKitko @URMed_AHF @URMed_AHF @URMC_DeptMed

Join us on Friday, August 22, 2025 at 12:00 PM EDT: Cardiac Allograft Vasculopathy Matthew Konerman MD. This session will highlight insights into the pathophysiology, diagnosis, and management of one of the most challenging complications in heart transplantation.

URMC’s Sarcoidosis Program was nominated by a grateful patient to be recognized by the City of Rochester. Kelly Cheatle presented the proclamation. Sarcoidosis is a challenging disease. The great work of URMC has improved patient lives #sarcoid #roc #urmc

Thought-provoking study suggesting to the best time for elective surg in pts w NSTEMI & DES is between 90-180 days. In pts w NSTEMI not revascularized, risk of MACCE/mortality did not level off -may be no benefit in waiting 60d (but higher risk w/i 30d) pubmed.ncbi.nlm.nih.gov/39475957/

Presence of AHFTC in OR at VAD implant=RV protective strategy. Dynamic discussions with CTS/Anesthesia on gtts, hemodynamics, rhythm Rx, optimal RPM. Enhances post-op care in CTICU knowing exactly what transpires in OR. Same for ♥️ Tx. Love being in OR with our surgeons.

@SangjinLee17 This was part of our daily routine when we were both fellows in Minnesota. CV surgery and HF need to work closely for the best patient outcomes!!!